SUMMARY Gold salts may attenuate inflammatory processes by inhibiting interleukin 1 production. It is shown that sodium aurothiomalate does not act as an antipyretic after intravenous injection of two pyrogens into rabbits. Consequently, it cannot suppress interleukin 1 production, a conclusion confirmed by an in vitro lymphocyte activating factor assay. Chronic sodium aurothiomalate treatment, however, did depress the blood leucocyte count significantly.
Gold treatment has been used in the management of rheumatic disease for most of this century, and yet its mechanism of action has not been established. ' 2 In rheumatoid arthritis gold alters the function of phagocytes at the site of inflammation.2-5 Phagocytes play a major part in chronic inflammatory reactions through their capacity to ingest and degrade materials6 and to secrete a number of biologically active substances,7 8 which appear to mediate the inflammation. Gold particles accumulate in synovial macrophages' 3 and inhibit lysosomal enzyme activity.5 Mononuclear phagocytic activity is suppressed in patients with rheumatoid arthritis who receive gold treatment.9 Also, prolonged incubation with sodium aurothiomalate reduces the function of human mononuclear phagocytes as accessory cells in the induction of cellular immune responses in vitro. 4 We do not know whether gold compounds also interfere with the capacity of phagocytes to secrete mediators of inflammation, including the plenipotentiary mediator interleukin 1 (IL1 The lymphocyte activating factor assay showed ILI activity only in supernatants from control monocytes and those incubated with the low concentration of sodium aurothiomalate (2.5 !Ig/ml), in which ILI activity was 20% lower than control. The Table shows why there was an apparent reduction of ILl at 2-5 ltg/ml concentration and an absence of activity at higher concentrations: even at low concentration aurothiomalate killed almost all the monocytes. Indeed, when ILl production was expressed per viable monocyte, production was enhanced in the presence of aurothiomalate.
Was the production of ILI per viable leucocyte also enhanced in vivo? We measured the total leucocyte count in the rabbits before (mean (SE) 7-2 (1-5)x109/l) and after (3-7 (1-6)x109/l) treatment with 2 mg of intramuscular aurothiomalate a day for four weeks. The decline was highly significant (p<0-01, n=5, unpaired t test). The finding that fever was unaffected despite a halving in leucocyte count leads us to believe that, if anything, ILI production per leucocyte was enhanced in vivo too. We conclude that sodium aurothiomalate treatment, although it affects leucocyte count, does not affect fever, and therefore cannot inhibit ILI production. This conclusion was supported by direct measurements of ILI production.
